Frontlight ResearchEarly access
CompletedPhase 2
Psilocybin in alcohol use disorder with comorbid depression - Randomized double-blind controlled pilot study.
Key facts
- Who runs it
- Centre Hospitalier Universitaire De Nimes
- Where
- France1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- Phase
- Phase 2
- People taking part
- 30 people enrolled
- Started
- 5 Feb 2024
- Ended
- 5 Mar 2025
- Type of study
- Interventional
- Record updated
- 21 March 2024
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 22 criteriaShow less
Who can take part
- A patient with a confirmed DSM-5 diagnosis of severe alcohol use disorder
- BDI II score (Beck Depression Inventory) ≥ 14
- The last drink must have been consumed between 60 and 14 days before the inclusion visit
- The patient must have had at least 1 HDD during the last drinking period
- The patient must have given his/her informed and signed consent
- The patient must be insured or beneficiary of a health insurance plan
- The patient is at least 18 years old
Who cannot take part
- Schizophrenic disorder, or any history of psychotic disorder as judged by the clinician
- History of hallucinogen use disorders, any use in the past year or > 25 lifetime uses
- First-degree relative with a diagnosis of psychotic disorder or type 1 bipolar disorder
- Patients with dementia or severe cognitive impairment
- Medical conditions that would prevent safe participation in the trial
- Dependence on cocaine, psychostimulants, opioids or cannabis (last 12 months)
- Current non-medical use of cocaine, psychostimulants or opioids (past 30 days)
- Severe ECG anomalies
- No access to email
- Insufficient understanding of French to complete questionnaires
- past or current manic or hypomanic episode
- Need for antipsychotic treatment that may interfere with psilocybin
- Suicidal ideation in progress, scripted (as judged by the clinician)
- High risk of negative emotional or behavioral response based on investigator's clinical judgment
- Score CIWA-R ≥ 8
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
To assess the feasibility of a trial comparing psilocybin with very low-dose psilocybin (control) in alcohol use disorder with depressive symptoms.
Data and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Record updated
- 21 March 2024